Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers


February 10, 2016 12:14 AM ET

Pharmaceuticals

Company Overview of Lycera Corp.

Company Overview

Lycera Corp., a biopharmaceutical company, discovers and develops oral immune modulators for the treatment of patients with autoimmune diseases and cancers. Its product pipeline includes LYC-30937, an ATPase modulator for the treatment of inflammatory bowel disease; oral RORgamma agonists for diverse applications in immune-oncology; and Rho kinase inhibitors, histone deacetylase 6 inhibitors, RORgt antagonists, and collaboration targets. Lycera Corp. was founded in 2006 and is headquartered in Ann Arbor, Michigan.

2800 Plymouth Road

NCRC

Building 26

Ann Arbor, MI 48109

United States

Founded in 2006

Phone:

734-233-3060

Key Executives for Lycera Corp.

Chief Executive Officer, President and Director
Age: 56
Co-Founder, Chief Scientific Officer and Director
Co-Owner
Chief Financial Officer
Senior Vice President of Biology
Compensation as of Fiscal Year 2015.

Lycera Corp. Key Developments

Lycera Corp. Enters into License Agreement with Celgene Corporation

Lycera Corp. announced that it entered into a license agreement with its collaboration partner Celgene Corporation.  Under the agreement, Lycera granted to Celgene an exclusive license for Lycera's portfolio of novel ex vivo RORgamma agonist compounds. Lycera is the leader in discovering and developing selective and potent oral agonists that target RORgamma, a master control switch of immune system activation, for the potential treatment of a broad range of cancers. While Lycera has developed orally bioavailable RORgamma agonists that have demonstrated single agent therapeutic activity in multiple animal models of cancer, ex vivo treatment with RORgamma agonist compounds has been shown to enhance the therapeutic benefit of adoptive T-cell therapy by improving both immune cell persistence and activation. Under the terms of the license agreement, Lycera received a $17.5 million upfront cash payment and has the potential to receive an additional near-term milestone payment of $5 million. In June 2015, Lycera and Celgene entered an exclusive global collaboration to take forward Lycera's proprietary product development pipeline for cancer and immune-mediated diseases. Key programs being advanced under this collaboration include LYC-30937 EC and Lycera's RORgamma agonists, as well as earlier-stage programs including a Rho-associated protein kinase 2 (ROCK2) inhibitor. As part of the strategic collaboration agreement, Celgene obtained the exclusive right to acquire Lycera upon conclusion of the option period or achievement by Lycera of pre-specified clinical milestones. During the option period, Lycera retains full control of its research and development programs. Following the exercise of the option to acquire Lycera, shareholders will also be eligible to receive future success-based milestones.

Lycera Corp. Presents at Boston Biotech East West CEO Conference, Jan-09-2016 09:55 AM

Lycera Corp. Presents at Boston Biotech East West CEO Conference, Jan-09-2016 09:55 AM. Venue: Four Seasons Hotel, 757 Market St., San Francisco, CA 94103, United States. Speakers: Paul J. Sekhri, Chief Executive Officer, President and Director.

Lycera Corp. Presents at Boston Biotech Conferences 2015, Nov-12-2015 02:00 PM

Lycera Corp. Presents at Boston Biotech Conferences 2015, Nov-12-2015 02:00 PM. Venue: Apella, 450 East 29th Street, NY 10016, New York, United States.

Similar Private Companies By Industry

Company Name Region
KeyBay Pharma, Inc. United States
Lantibio, Inc. United States
Critical Care Systems International, Inc. United States
Anchen Pharmaceuticals, Inc. United States
GynoPharma Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
June 12, 2015
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Lycera Corp., please visit www.lycera.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.